Cargando…
Corrigendum: Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
The authors wish to make the following corrections to their article: Sapin C, Hartry A, Kamat SA, Beillat M, Baker RA, Eramo A. Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis. Drugs in Context 201...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Just Medical Media Limited
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499894/ https://www.ncbi.nlm.nih.gov/pubmed/28706556 http://dx.doi.org/10.7573/dic.212504 |
Ejemplares similares
-
Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis
por: Sapin, Christophe, et al.
Publicado: (2016) -
Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate
por: Potkin, Steven G., et al.
Publicado: (2016) -
Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Publicado: (2019) -
Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece
por: Einarson, Thomas R, et al.
Publicado: (2012) -
PM417. Relationship between response to aripiprazole once-monthly and paliperidone palmitate on work readiness and functioning: a post-hoc analysis of QUALIFY, a head-to-head study in schizophrenia
por: Salzman, Phyllis, et al.
Publicado: (2016)